Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Hematostatic function in myeloproliferative diseases].

Xiao Zhu1, Min-Fei Pei, Min Xu

  • 1Department of Oncology and Hematology, The Forth Hospital of Changsha, Changsha 410006, China.

Zhongguo Shi Yan Xue Ye Xue Za Zhi
|November 14, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Relationship between TET2 Gene SNP rs3733609 C/T and JAK2V617F Allele Burden in Patients with Myeloproliferative Neoplasms].

Zhongguo shi yan xue ye xue za zhi·2019
Same author

Chinese guidelines for treatment of adult primary immune thrombocytopenia.

International journal of hematology·2018
Same author

Molecular characterization and therapeutic reaction to dasatinib in a CML patient harboring a novel e8a2 BCR-ABL1 transcript with a somatic mutation in TP53BP2 and cadherin-10 genes.

Leukemia & lymphoma·2017
Same author

[Effect of Icaritin on Proliferation and Apoptosis of THP-1 Cell and Its Mechanism].

Zhongguo shi yan xue ye xue za zhi·2017
Same author

Bone marrow-derived innate macrophages attenuate oxazolone-induced colitis.

Cellular immunology·2016
Same author

Two novel compound heterozygous mutations associated with types I and II protein C deficiency with unusual phenotypes.

Thrombosis research·2016
Same journal

[Research Progress on the Bone Marrow Microenvironment in Beta-Thalassemia --Review].

Zhongguo shi yan xue ye xue za zhi·2026
Same journal

[Research Progress of CAR-T Cell Therapy in Autoimmune Diseases --Review].

Zhongguo shi yan xue ye xue za zhi·2026
Same journal

[Research Progress of Chimeric Antigen Receptor T Cell Therapy in Acute Myeloid Leukemia--Review].

Zhongguo shi yan xue ye xue za zhi·2026
Same journal

[Research Progress in Venetoclax-Based Combination Therapy in Acute Myeloid Leukaemia--Review].

Zhongguo shi yan xue ye xue za zhi·2026
Same journal

[Advances in the Treatment of Acute Myeloid Leukemia with <i>TP53</i> Mutations-Review].

Zhongguo shi yan xue ye xue za zhi·2026
Same journal

[Analysis of Risk Factors and Clinical Characteristics of Early Death in Patients with Hemophagocytic Syndrome].

Zhongguo shi yan xue ye xue za zhi·2026
See all related articles

Patients with myeloproliferative diseases (MPD) often exhibit abnormal platelet aggregative function. Careful consideration of anti-platelet drug use is advised due to high rates of platelet dysfunction in MPD.

Area of Science:

  • Hematology
  • Oncology
  • Hemostasis and Thrombosis

Context:

  • Myeloproliferative diseases (MPD) are a group of disorders characterized by the overproduction of myeloid cells.
  • Hemostatic function, particularly platelet aggregation, can be altered in MPD patients.
  • Understanding these alterations is crucial for managing patient care and treatment.

Purpose:

  • To investigate changes in early hemostatic function in patients diagnosed with MPD.
  • To explore the clinical significance of these hemostatic changes when correlated with patient data.
  • To assess platelet aggregative function using various inducers and measure plasma von Willebrand factor levels.

Summary:

  • Platelet aggregative function was significantly decreased in 35 MPD patients compared to healthy controls across four different inductors (ristomycin, adenosine diphosphate, collagen, adrenine).

Related Experiment Videos

  • Plasma von Willebrand factor-associated antigen (vWF: Ag) levels showed no significant difference between MPD patients and controls.
  • Plasma von Willebrand factor-ristomycin cofactor (vWF: Rco) activity was normal in most MPD patients, with one exception of essential thrombocytosis (ET) exhibiting significantly low activity, warranting further research into vWF polymer deficiency.

    • Impact:

    • The study highlights a high prevalence of abnormal platelet aggregative function in MPD patients.
    • Findings suggest that the clinical application of anti-platelet drugs in MPD patients requires careful consideration due to potential platelet dysfunction.
    • Further research is needed to understand the implications of vWF polymer shortage in specific MPD cases.